TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01397630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Accelerated Oxytocin Titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Accelerated Oxytocin Titration
Study: NCT03099538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Subcutaneous injection
Study: NCT01372579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study: NCT00724256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftibuten
Description: ceftibuten 9mg/kg once a day for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftibuten
Description: ceftibuten 9mg/kg once a day for 10 days.
Study: NCT01835093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipepidine Hibenzate
Study: NCT02533362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANF-Rho
Description: Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)
Study: NCT02628834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial mobilization
Description: The patient will lie on prone position with knee extension and therapist put the patient's plantar surface to her femoral region. Achilles, tibialis posterior, perenous longus and brevis distal tendons, gastrocnemius proximal tendons, hamstring's distal tendons will be mobilized at first stage. The second stage of fascia mobilization included the deep fascial mobilization of posterior crural muscle trunks. After that, the skin also will be gently mobilized. During fascial mobilization, once the spastic muscles relaxation will appeared, the ankle will move to dorsiflexion gradually. FM will carry out for 15 minutes for each foot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Exercise
Description: Patients will receive also stretching exercises consisted of 30 s stretching and 10 s resting periods and will carry out for 15 minutes for each foot at second day after the first evaluation.
Study: NCT03301285

Intervention type: DRUG
Intervention: Zoledronic Acid
Description: Treatment of osteoporosis
Study: NCT01056965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: davunetide (AL-108, NAP)
Description: Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with davunetide 15 mg administered intranasally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
Study: NCT01535859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 8 days.
Study: NCT01829308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The brief interventions are delivered by behavioral health counselors (Specialist)
Description: Behavioral Health Specialists perform the brief intervention. The screening and referral to treatment processes remain the same as with the Generalist condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The brief interventions are delivered by the primary care provider (Generalist)
Description: Primary care providers perform the brief intervention. The screening and referral to treatment processes remain the same as with the Specialist condition.
Study: NCT03206619

Intervention type: OTHER
Intervention: Social, Local and Mobile
Description: Patients in a smoking cessation program will use a mobile application to receive messages and rate them from their smartphones. The messages patient will receive belong to one of the following five topics: general motivation, diet tips, physical exercise tips, personal performance, and the benefits of being a non-smoker. For each one of these topics, there will be a pool of 150 different messages with tailored information for the patient. Topics and messages were approved by a smoking cessation psychologist and a pulmonologist. The selection of the time the messages have to be sent, and the message topic is selected by an health recommender system algorithm based on the patients' user profile (demographic information, message rating information, and app interaction information).
Study: NCT01127828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic yoghurt (Cultura)
Description: 200 ml per day
Study: NCT03192358

Intervention type: DIAGNOSTIC_TEST
Intervention: Videofluoroscopic Swallowing Examination
Description: During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.

Intervention type: DIAGNOSTIC_TEST
Intervention: Videofluoroscopic Swallowing Examination
Description: During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.

Intervention type: OTHER
Intervention: Tongue Strength Measurement
Description: We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.~Tongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy).

Intervention type: OTHER
Intervention: Tongue Strength Measurement
Description: We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.~Tongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy).
Study: NCT01915303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide with or without cabergoline
Description: The trial consisted of Pasireotide-untreated patients who started pasireotide 0.6mg twice a day for 8 weeks. If biochemical control was not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose was increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline was added and patients began combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline was increased to 1.0mg once a day. Patients could also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients continued with the combination treatment for 8 weeks. If biochemical control was not not achieved by the end of the 8 week period, the dose of cabergoline was increased to 1mg once a day.
Study: NCT01716416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT02925338

Intervention type: OTHER
Intervention: QOL questionaire
Description: Health assessment questionnaire disability index for rheumatoid polyarthritis questionnaire
Study: NCT02078856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3384

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A3384
Study: NCT04096768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
Study: NCT00146848

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices
Description: All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices
Description: All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices
Description: All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm.
Study: NCT03113890

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Phlebotomy - Folate
Description: This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)

Intervention type: GENETIC
Group type: OTHER
Intervention: Phlebotomy - Folate
Description: This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cheek Swab
Description: Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.

Intervention type: GENETIC
Group type: OTHER
Intervention: Cheek Swab
Description: Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-report surveys
Description: At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Self-report surveys
Description: At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
Study: NCT01952808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face family mentoring and education sessions
Description: A total of 13 home visits will be completed over a 6 month period. In addition to an introductory/orientation visit, 12 home visits will consist of family mentoring/educational sessions focused on physical activity and healthy nutrition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: During months 7-12, a total of up to 12 phone calls will be completed. Follow-up calls will consist of a progress report from families on physical activity and healthy diet progress/goals, along with brief content follow-up and re-enforcement points from the 12 intervention sessions.
Study: NCT01245569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foster® 100/6 µg/unit dose
Description: Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Accuhaler® 500/50 µg/actuation
Description: Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
Study: NCT04090372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: evaluation of pre-op planning using Traumacad
Description: The study will be compare pre-op planning with standard condition or with TraumaCad

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: evaluation of pre-op planning using Traumacad
Description: The study will be compare pre-op planning with standard condition or with TraumaCad
Study: NCT01105767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental training, education and hygiene
Description: Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental training, education and hygiene
Description: Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.
Study: NCT01279941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Team-based intervention
Description: The intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, one-hour weekly sessions incorporated into a team's usual work time activities, with four follow-up booster sessions after twelve months.
Study: NCT00401232

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Collection
Description: Blood Collection
Study: NCT02840617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Study: NCT03123406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Description: Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Description: Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Description: Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
Study: NCT01411735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 2.5mg titrated up to 10mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2.5mg titrated up to 10mg twice daily.
Study: NCT01318824

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Intermittent Positive Pressure Ventilation (NIPPV)
Description: The Control group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bi-Level Positive Airway Pressure (BIPAP)
Description: BiPAP group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
Study: NCT02379689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable placental tissue extract called BioDGenesis (Active Product)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02410889

Intervention type: OTHER
Intervention: EEG-fMRI scanning
Description: Patients undergo EEG-fMRI scanning
Study: NCT03449641

Intervention type: DEVICE
Group type: OTHER
Intervention: Positive airway pressure (PAP)
Description: Positive airway pressure (PAP) is a mode of respiratory ventilation used in the treatment of sleep apnea.
Study: NCT00228553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 100 to 250 mg/day
Description: Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
Study: NCT03060070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: 20ml of 0.25% bupivacaine will be injected in each side of the TAP block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: 20ml of 0.25% bupivacaine will be injected in each side of the TAP block
Study: NCT03246386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posaconazole Injection [Noxafil] 300mg
Description: Single dose by intravenous infusion 300mg
Study: NCT03618511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Financial Incentive: Participants will receive monthly financial incentives each time they refill the ART medication on time for six months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Reminders: Participants will receive monthly reminder phone calls before their ART medication refill is due for six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive and Reminders
Description: Interaction: Participants receive both the Financial Incentives and Reminder Calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information: show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma-relieving
Description: Stigma-Reliving: Upon recruitment, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information and Stigma-relieving
Description: Information and Stigma-relieving: Upon recruitment, show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART. In addition, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
Study: NCT02300454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-slip element balloon (NSE)
Description: Lacrosse® NSE and SeQuent® Please drug coated balloon (DCB)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Balloon
Description: Non-compliant balloon and SeQuent® Please drug coated balloon (DCB)
Study: NCT02318472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VACOped orthosis
Description: Weight-bearing orthosis with adjustable range of motion of the ankle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plaster cast
Description: Lower limb plaster cast
Study: NCT01731678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
Study: NCT00430170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole
Description: Dipyridamole 2x200mg 7day per os

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dipyridamole
Description: Dipyridamole 2x200mg 7day per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine
Description: caffeine 4mg/kg iv
Study: NCT04206449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic decision PSG
Description: Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic decision Infrared thermgraphy system
Description: Also randomizing for Infrared thermography system
Study: NCT03166332

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Mediterranean diet supplemented with extra-virgin olive oil and nuts

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness-Based Stress Reduction program (MBSR)